drugset
drugset / Trial / NCT05157945

ALTO-300 in Depression (ALTO-300-004)

NCT05157945 ↗

Phase 2 Completed 148 enrolled Alto Neuroscience
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to collect biologically-based data for defining predictors and correlates of the effects of ALTO-300.

Timeline

Start
2022-02-03
Primary completion
2023-04-26
Completion
2023-05-05

Drugs

EvaluationDrugModalityDoseRoute
Subject ALTO-300 Unknown — Oral

Indications

major depressive disorder